Expression of vascular endothelial factor protein in the tumor tissues of patients with Stages I-II ovarian cancer
https://doi.org/10.17650/1994-4098-2010-0-3-73-76
Abstract
To define tumor markers is presently the most interesting and promising direction for the diagnosis of malignancies. The expression of the major angiogenesis factor vascular endothelial growth factor (VEGF) in primary tumor tissue was studied in ovarian cancer (OC) patients to define the prognostic value of the marker.
The study enrolled 48 patients with OC. The immunohistochemical technique was used to examine VEGF expression in the primary tu- mor tissue. The frequency of VEGF expression, which was associated with lower relapse-free survival rates, was found to be high (85.4%) in OC patients (p > 0.05).
The tumor expression of the angiogenic factor VEGF was shown to provide prognostic information in early-stage ovarian epithelial cancer.
About the Authors
V. L. Karapetyan
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. V. Stepanova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. Yu. Baryshnikov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
S. O. Nikogosyan
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. V. Kuznetsov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
T. Sh. Tagibova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Бохман Я.В. Руководство по онкогинекологии. Л.: Медицина, 1989.
2. Бохман Я.В., Вихляева Е.М., Лившиц М.А. Опухоли яичников: сборник научных трудов. Иркутск, 1990; с. 16–26.
3. Жорданиа К.И. Злокачественные эпителиальные опухоли яичников. Совр онкол 2000;2(2):14–22.
4. Нечаева И.Д. Опухоли яичников. Л.: Медицина, 1987.
5. Барышников А.Ю., Шишкин Ю.В. Программированная клеточная смерть (апоптоз). Рос онкол журн 1996;(1):58–61.
6. Bodner S., Minna J., Jensen S. et al. Expression of mutant p53 proteins in lung cancer correlates with the loss of p53 gene mutation. Oncogene 1992;7:743–9.
7. Жорданиа К.И. Роль опухолеассоциированных маркеров в диагностике и лечении рака яичников. В сб.: Современные экспериментальные и клинические подходы к диагностике и рациональному лечению рака яичников. Под ред. В.А. Горбуновой. М., 2001; с. 58–65.
8. Ferrara N., Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359–64.
9. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25.
10. Folkman J. Tumor angiogenesis therapeutic implications. N Eng J Med 1971;285:1182–6.
11. Карамышева А.Ф. Ангиогенез опухоли: механизмы, новые подходы к терапии. В кн.: Канцерогенез. Под ред. Д.Г. Заридзе. М., 2000; с. 298–309 (обзор).
12. Cao Y., Linden P., Farnebo J. et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998;95:14389–94.
13. Davidson B., Goldberg I., Kopolovic J. Expression of angiogenesis-related genes in ovarian carcinoma – a clinicopathologic study. Clin Exp Metastas 2000;18:501–7.
14. Garzetti G., Giavattini A., Lucarini G. et al. Expression of vascular endothelial growth factor relatied to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer 1999;85(10):2219–25.
15. Paley P., Goff B., Gown A. et al. Alterations in SPARS and VEGF immunoreactivity in ovarian cancer. Gynecol Oncol 2000;78:336–41.
16. Yamomoto S., Konishi Y., Kuroda H. et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221–7.
17. Fujimoto J., Sakaguchi H., Aoki I. et al. Clinical implications of expression of vascular endothelial growth factor in metastatic lesion of ovarian cancer. Br J Cancer 2001;85(3):313–6.
18. Paley P., Staskus K., Gebhard K. et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80(1):98–106.
Review
For citations:
Karapetyan V.L., Stepanova E.V., Baryshnikov A.Yu., Nikogosyan S.O., Kuznetsov V.V., Tagibova T.Sh. Expression of vascular endothelial factor protein in the tumor tissues of patients with Stages I-II ovarian cancer. Tumors of female reproductive system. 2010;(3):73-76. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-3-73-76
Views:
504
Email this article 